<DOC>
	<DOCNO>NCT00211016</DOCNO>
	<brief_summary>The purpose study compare clinical response rate doripenem versus comparator patient ventilator-associated pneumonia ( VAP ) .</brief_summary>
	<brief_title>Doripenem Treatment Ventilator-Associated Pneumonia</brief_title>
	<detailed_description>Doripenem antibiotic medication yet approve US FDA . This phase 3 , multicenter , prospective , randomize , open-label study doripenem versus comparator ass effectiveness safety doripenem treatment VAP adult patient . The study consist screen phase , open-label treatment phase , follow-up . The treatment duration 7 14 day . The primary endpoint clinical response rate doripenem early follow-up visit . The patient receive either doripenem comparator 7 14 day .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<criteria>Patient receive mechanical ventilation &gt; 24 hour Presence new progressive infiltrate chest xray Believed study entry ventilatorassociated pneumonia cause solely pathogen ( ) resistant certain antibiotic History moderate severe hypersensitivity reaction certain antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Ventilator-Associated Pneumonia</keyword>
</DOC>